Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Nora AI
  • Q&A
  • About Us
    • Our Coverage
    • Team
Regulatory press release

MEDI: SECOND QUARTER AND FIRST HALF FINANCIAL RESULTS 2023 FOR MEDISTIM ASA

Medistim
Sales for the second quarter ended at MNOK 137.4 (MNOK 117.5), an increase of
16.9%. Sales for first half ended at MNOK 266.6 (MNOK 233.6), an increase of
14.1%.

Currency neutral sales of own products was up 4.0% for the quarter and 2.5% for
the first half.

Operating profit (EBIT) for the quarter is up 13.1% and ended at MNOK 42.2, an
EBIT margin at 30.7% (MNOK 37.3 an EBIT margin at 31.8%). For the first half
EBIT is up 6.9% and ended at MNOK 75.7 an EBIT margin at 32.6% for the first
half (MNOK 70.8 an EBIT margin at 35.3%).

Medistim established direct sales organizations in both Canada and China in Q2
and continues to strengthen its organization worldwide.

Medistim announced its participation in a groundbreaking cardiac surgery trial
dedicated to women, ROMA-W.

A dividend of NOK 4.50 per share, a total of MNOK 82.2, was paid 5th of May.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.